‹ News

ORKA SRZN IBTA CGON RDNW CE NP BWLP SEDG CRL

ORKA: Ascending Triangle detected on 1 Apr 2026

Overall Score

83 of 100

Strong

Win Probability

63%

Moderate

Reward / Risk

0.9 : 1

$0.77 reward $-0.82 risk

Summary Context Technical Indicators

Current Setup

ORKA is forming an ascending triangle pattern with a near-term breakout setup. The structure score of 15.0 out of 15 reflects clean higher lows within a tight range bounded by resistance at $48.28 and support at $44.82. At current price $49.05, the stock trades slightly above resistance, establishing a fresh breakout trigger point. Volume is 1,022,628 shares (volume ratio 1.33), above the 20-day average, confirming breakout interest. The overall pattern quality is strong at 83.0, driven by excellent structure and breakout scores (13.0), though volume confirmation at 12.0 leaves modest room for validation.

Stock Context

On March 16, 2026, Leerink Partners raised its price target on ORKA from $58.00 to $86.00, signaling renewed analyst confidence. Guggenheim reaffirmed a 'buy' rating with a $60.00 price target on March 13, 2026. The company reported $479.6 million in cash and marketable securities as of December 31, 2025, providing strong financial runway. ORKA-001 EVERLAST-A 16-week data is expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026. The company announced positive interim Phase 1 data from its ORKA-002 trial in January 2026 and initiated EVERLAST-B Phase 2b trial in December 2025. These catalysts and strong balance sheet position are driving the bullish pattern now, with multiple near-term data events expected throughout 2026.

What to Expect

The conservative measured move target is $52.07, representing 6% upside from the current $49.05 breakout level. A successful breakout requires sustained volume above the current 1.33x volume ratio to overcome resistance overhead. The pattern invalidates if price closes below key support at $44.82. The win probability of 63.3% suggests better-than-even odds of reaching the conservative target or higher. Given the biotech sector's sensitivity to clinical data, momentum above $50 should trigger further extension toward the Leerink $86 target if EVERLAST-A data in Q2 2026 proves positive.

Risk Factors

CEO Lawrence Otto Klein sold 1,729 shares on March 16 at $41.30, though this represents only a 0.19% decrease in his position and may be routine. RSI at 72.86 indicates overbought conditions, signaling elevated near-term pullback risk after the 58.7% three-month gain. Wall Street Zen downgraded ORKA from 'hold' to 'sell' on March 8, 2026, creating conflicting analyst views. Phase 2a EVERLAST-A results are expected in 2H 2026, but meaningful revenue is not anticipated until 2031, highlighting the long-term, high-risk clinical profile. The broader market operates under a bearish regime (-0.46), and the Health Care sector is also bearish (-0.09), creating headwinds for biotech momentum. Clinical trial failure or delayed data could rapidly reverse the pattern.

Market & Sector Regime

Market

Bearish -0.46

-1.0 0 +1.0

Health Care Sector

Bearish -0.09

-1.0 0 +1.0

Other Patterns Detected Today

Bull Flag

59 days in pattern

Moderate 27.7

Bullish Pennant

17 days in pattern

Weak 25.3

Overall Score

40 of 40

Exceptional

Pattern Quality

20 of 20

Exceptional

Setup

11 of 20

Fair

R/R

12 of 18

Moderate

Context

Pattern Quality Score

15 of 15

Exceptional

Structure

13 of 13

Exceptional

Breakout

12 of 12

Exceptional

Volume

Recent Performance

+22.9%

+18.7%

+45.6%

+58.7%

Momentum & Trend

RSI (14)

72.9

Overbought

MACD Histogram

+0.77

Bullish

Bollinger Band Position

98.7%

Upper Band

Volatility & Risk

20-Day Volatility

1.12

Very High

ATR %

7.2%

High

Beta

0.93

Market

Volume Analysis

Volume Ratio

1.33x

Above Avg

20-Day Avg Vol

767K

shares / day

Current Volume

1.0M

shares traded

Price Levels

Target

$52.07

52W High

$49.32

Current

$49.05

Resistance

$48.28

Support

$44.82

Stop Loss

$44.59

52W Low

$5.49

Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.